<p>This study examined immunologic correlatives from a phase II study evaluating CRS207/GVAX vaccines in combination with anti-<a href="https://www.ncbi.nlm.nih.gov/gene/5133">PD1 </a>and anti-<a href="https://www.ncbi.nlm.nih.gov/gene/1493">CTLA4 </a>in metastatic pancreatic cancer (<a href="https://clinicaltrials.gov/study/NCT03190265?cond=NCT03190265&#x26;rank=1">NCT03190265</a>). Arm A received CRS207/GVAX with anti-PD1 and anti-CTLA4 therapy; Arm B received CRS207 with anti-PD1 and anti-CTLA4 therapy. Patients undergoing treatment in this trial had peripheral blood mononuclear cells (PBMCs) and tumor tissue biopsied serially at pre-treatment and on-treatment timepoints. Single-cell RNA/TCR sequencing was employed on PBMCs. Bulk RNA/TCR sequencing was employed on tumor tissues. We identified treatment-enriched inflammatory pathways as well as T cell repertoires.</p>

A Phase II Study: CRS207/GVAX Plus Anti-PD1 and Anti-CTLA4 Recruits    Mesothelin- and KRAS-Specific T cells into PDAC

Pancreatic Neoplasms study with RNA-Seq data on dbGaP (61 participants)

A Phase II Study: CRS207/GVAX Plus Anti-PD1 and Anti-CTLA4 Recruits Mesothelin- and KRAS-Specific T cells into PDAC

Description

Applying For Access

Summary